• 1
    Gordon RD, Fung JJ, Markus B et al. The antibody crossmatch in liver transplantation. Surgery 1986; 100: 705715.
  • 2
    Moore SB, Wiesner RH, Perkins JD, Nagorney DM, Sterioff S, Krom RA. A positive lymphocyte cross-match and major histocompatibility complex mismatching do not predict early rejection of liver transplants in patients treated with cyclosporine. Transplant Proc 1987; 19(Pt 3): 23902391.
  • 3
    Ogura K, Koyama H, Takemoto S, Terasaki PI, Busuttil RW. Significance of a positive crossmatch on outcome in human liver transplantation. Transplant Proc 1992; 24: 1465.
  • 4
    Ogura K, Terasaki PI, Koyama H, Chia J, Imagawa DK, Busuttil RW. High one-month liver graft failure rates in flow cytometry crossmatch-positive recipients. Clin Transplant 1994; 8(Pt 1): 111115.
  • 5
    Takaya S, Duquesnoy R, Iwaki Y et al. Positive crossmatch in primary human liver allografts under cyclosporine or FK 506 therapy. Transplant Proc 1991; 23(Pt 1): 396399.
  • 6
    Castillo-Rama M, Castro MJ, Bernardo I et al. Preformed antibodies detected by cytotoxic assay or multibead array decrease liver allograft survival: Role of human leukocyte antigen compatibility. Liver Transpl 2008; 14: 554562.
  • 7
    Goh A, Scalamogna M, De Feo T, Poli F, Terasaki PI. Human leukocyte antigen crossmatch testing is important for liver retransplantation. Liver Transpl 2010; 16: 308313.
  • 8
    Kasahara M, Kiuchi T, Takakura K et al. Postoperative flow cytometry crossmatch in living donor liver transplantation: Clinical significance of humoral immunity in acute rejection. Transplantation 1999; 67: 568575.
  • 9
    Fontana M, Moradpour D, Aubert V, Pantaleo G, Pascual M. Prevalence of anti-HLA antibodies after liver transplantation. Transpl Int 2010; 23: 858859.
  • 10
    Demetris AJ, Markus BH, Burnham J et al. Antibody deposition in liver allografts with chronic rejection. Transplant Proc 1987; 19(Suppl 5): 121125.
  • 11
    Demetris A, Adams D, Bellamy C et al. Update of the international banff schema for liver allograft rejection: Working recommendations for the histopathologic staging and reporting of chronic rejection. An Int Panel Hepatol 2000; 31: 792799.
  • 12
    Mizutani K, Terasaki P, Hamdani E et al. The importance of anti-HLA-specific antibody strength in monitoring kidney transplant patients. Am J Transplant 2007; 7: 10271031.
  • 13
    Batal I, Zeevi A, Lunz JG 3rd et al. Antihuman leukocyte antigen-specific antibody strength determined by complement-dependent or solid-phase assays can predict positive donor-specific crossmatches. Arch Pathol Lab Med 2010; 134: 15341540.
  • 14
    Singh N, Djamali A, Lorentzen D et al. Pretransplant donor-specific antibodies detected by single-antigen bead flow cytometry are associated with inferior kidney transplant. Outcomes Transplant 2010; 90: 10791084.
  • 15
    Agarwal A, Dar W, Watkins C et al. Donor-directed MHC class I antibody is preferentially cleared in sensitized recipients of combined liver/kidney transplants. Am J Transplant 2011; 11: 841847.
  • 16
    Lee PC, Zhu L, Terasaki PI, Everly MJ. HLA-specific antibodies developed in the first year posttransplant are predictive of chronic rejection and renal graft loss. Transplantation 2009; 88: 568574.
  • 17
    Hove WR, van Hoek B, Bajema IM, Ringers J, van Krieken JH, Lagaaij EL. Extensive chimerism in liver transplants: Vascular endothelium, bile duct epithelium, and hepatocytes. Liver Transpl 2003; 9 552556.
  • 18
    Ruiz R, Tomiyama K, Chinnakotla S et al. The positive crossmatch in liver transplantation: A risk factor for preservation injury? XXIII Int Cong Transplant Soc. 2010: Abstract 060.07.
  • 19
    Kozlowski T, Rubinas T, Nickeleit V et al. Liver allograft antibody-mediated rejection with demonstration of sinusoidal C4d staining and circulating donor-specific antibodies. Liver Transpl. 2011; 17: 357368.
  • 20
    Cruse J, Lewis R, Wang H. Immunology guidebook. San Diego : Elsevier Academic Press; 2004.
  • 21
    Zachary AA, Montgomery RA, Leffell MS. Factors associated with and predictive of persistence of donor-specific antibody after treatment with plasmapheresis and intravenous immunoglobulin. Hum Immunol 2005; 66: 364370.
  • 22
    Zachary AA, Leffell MS. Detecting and monitoring human leukocyte antigen-specific antibodies. Hum Immunol 2008; 69: 591604.
  • 23
    Moonka DK, Kim D, Kapke A, Brown KA, Yoshida A. The influence of induction therapy on graft and patient survival in patients with and without hepatitis C after liver transplantation. Am J Transplant 2010; 10: 590601.